A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients.

BACKGROUND Postsurgical thyrotropin (TSH)-stimulated serum thyroglobulin (Tg) level can be used to predict the likelihood of finding radioactive iodine (RAI) avid metastatic foci on postablation scanning. However, there is little data regarding the predictive value of a nonstimulated postoperative Tg obtained on levothyroxine therapy in patients being considered for recombinant human TSH (rhTSH)-assisted remnant ablation. METHODS The study included 290 intermediate-risk differentiated thyroid cancer (DTC) patients with a postsurgical nonstimulated Tg<10 ng/mL prior to rhTSH-assisted remnant ablation. Patients were stratified into four groups based on the postsurgical nonstimulated Tg value: Tg<0.6 ng/mL (n=146), Tg 0.6-0.9 ng/mL (n=76), Tg 1-5 ng/mL (n=51), and Tg>5-10 ng/mL (n=17). RAI avid metastatic foci were identified using post-therapy scanning with SPECT/CT (single photon emission computed tomography). RESULTS RAI avid metastases were identified in 16% (46/290) of patients, including 12% (17/146) with Tg<0.6 ng/mL, 14% (11/76) with Tg 0.6-0.9 ng/mL, 25% (13/51) with Tg 1-5 ng/mL, and 29% (5/17) with Tg>5-10 ng/mL (p=0.02). While 99% of the RAI avid foci were located in the neck, lung uptake was seen in one patient with Tg<0.6 ng/mL (0.7%, 1/146), one patient with Tg 0.6-0.9 ng/mL (1.3%, 1/76), and 2 patients with Tg>5-10 ng/mL (11%, 2/17 patients). CONCLUSIONS A postoperative nonstimulated Tg<0.6 ng/mL does not exclude identification of RAI avid metastatic foci on postablation SPECT/CT scanning in intermediate-risk DTC patients. Therefore, patient selection for RAI ablation in the intermediate-risk group must be based on an integration of multiple risk factors rather than any single clinicopathologic risk factor.

[1]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[2]  E. Guedj,et al.  Early sequential changes in serum thyroglobulin after radioiodine ablation for thyroid cancer: possible clinical implications for recombinant human thyrotropin-aided therapy. , 2006, Thyroid : official journal of the American Thyroid Association.

[3]  P. Rosário,et al.  Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence. , 2011, Thyroid : official journal of the American Thyroid Association.

[4]  B. Wolffenbuttel,et al.  The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. , 2008, European journal of endocrinology.

[5]  V. Guimarães,et al.  Thyroglobulin before Ablation and Correlation with Posttreatment Scanning , 2005, The Laryngoscope.

[6]  B. Wolffenbuttel,et al.  Thyroglobulin (Tg) recovery testing with quantitative Tg antibody measurement for determining interference in serum Tg assays in differentiated thyroid carcinoma. , 2006, Clinical chemistry.

[7]  L. Ceriani,et al.  Thyroglobulin measurement before rhTSH‐aided 131I ablation in detecting metastases from differentiated thyroid carcinoma , 2008, Clinical endocrinology.

[8]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[9]  A. Stojadinovic,et al.  The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. , 2012, The Journal of clinical endocrinology and metabolism.

[10]  S. Larson,et al.  The Effect of Posttherapy 131I SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer , 2010, The Journal of Nuclear Medicine.

[11]  D. Lee,et al.  Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  F. Verburg,et al.  Ruling out 131I ablation in low-risk differentiated thyroid carcinoma basing on thyroglobulin measurement. , 2011, Thyroid.

[13]  R. Tuttle,et al.  Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. , 2012, The Journal of clinical endocrinology and metabolism.

[14]  R. Tuttle,et al.  Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer , 2011, Clinical endocrinology.

[15]  S. Larson,et al.  Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.

[16]  John T. Chang,et al.  The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. , 2010, Thyroid : official journal of the American Thyroid Association.

[17]  L. Hann,et al.  Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. , 2011, Thyroid : official journal of the American Thyroid Association.

[18]  A. Miyauchi,et al.  Excellent Prognosis of Patients with Solitary T1N0M0 Papillary Thyroid Carcinoma Who Underwent Thyroidectomy and Elective Lymph Node Dissection Without Radioiodine Therapy , 2010, World Journal of Surgery.

[19]  S. Filetti,et al.  BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. , 2007, The Journal of clinical endocrinology and metabolism.

[20]  L. Ceriani,et al.  Undetectable Thyroglobulin in Patients With Differentiated Thyroid Carcinoma and Residual Radioiodine Uptake on a Postablation Whole-Body Scan , 2011, Clinical nuclear medicine.